Staedtisches Klinikum Lueneburg gGmbH

At Staedtisches Klinikum Lueneburg gGmbH, a major part of the research portfolio focuses on digestive system diseases, especially Crohn’s disease and ulcerative colitis. These studies are mainly designed to test new therapies, improve disease control, and better understand how treatment can support lasting remission in people with moderate to severe inflammatory bowel disease.

• Clinical studies in Crohn’s disease and ulcerative colitis
• Evaluation of new targeted therapies and biologic treatments
• Research on improving remission, healing, and long-term disease control
• Studies of microbiome-based approaches for active ulcerative colitis

This area reflects a strong interest in gastroenterology and in developing more effective options for patients with chronic intestinal inflammation.

The site also conducts research in immune system diseases and immune system phenomena, with a clear link to inflammatory conditions driven by abnormal immune activity. The trials are aimed at evaluating safety, efficacy, and the broader biological effects of new treatments that may help control immune-mediated disease.

• Trials in immune-mediated inflammatory disease
• Assessment of targeted therapies for immune-related conditions
• Focus on understanding treatment effects on disease activity and remission
• Support for research into long-term safety and tolerability

These studies highlight the clinic’s role in advancing care for conditions where the immune system plays a central role in disease development.

Research in cardiovascular diseases at this hospital includes studies in acute ischemic stroke and stroke linked with atrial fibrillation. The main purpose is to evaluate treatment strategies that may improve recovery, reduce future cardiovascular events, and support better outcomes after a stroke.

• Studies in acute ischemic stroke treatment
• Research on stroke prevention in patients with atrial fibrillation
• Evaluation of therapies intended to improve functional outcomes
• Clinical work focused on reducing adverse cardiovascular events

These trials show an active interest in urgent-care research and in finding better ways to protect patients after serious vascular events.

The oncology research portfolio includes neoplasms, especially early breast cancer with HR+/HER2- and HER2-positive disease. The trials are designed to assess new adjuvant treatment approaches, improve survival, and refine strategies for patients at risk of recurrence.

• Studies in early breast cancer subtypes
• Testing new adjuvant treatment combinations
• Research aimed at improving disease-free survival
• Focus on patients with higher risk of recurrence

At Staedtisches Klinikum Lueneburg gGmbH, this field connects cancer care with efforts to make treatment more effective and more precisely matched to patient risk.